Back to conferencesAdd to calendar
Live Webinar
Controversies in Alcohol-Associated Liver Disease
Your seat
Saturday, August 1
12:00 PM UTC
Format
Online
Price
Free
Join link opens 10 minutes before the conference.
About the Speaker
HepatologyProf. Gene Im
MD
Professor of Medicine · Columbia University Irving Medical Center and NewYork-Presbyterian Hospital · USA
Dr. Gene Y. Im is a transplant hepatologist and gastroenterologist at Columbia University Irving Medical Center and NewYork-Presbyterian Hospital. He serves as Director of the Alcohol-associated Liver Disease Program (ADAPT), a multidisciplinary initiative dedicated to advancing the care of patients with alcohol-associated liver disease (ALD) through clinical innovation, research, and education. Internationally recognized for his expertise in ALD, alcohol-associated hepatitis, and liver transplantation, Dr. Im has contributed to several influential practice guidelines, including the AASLD 2019 Alcohol-Associated Liver Disease Practice Guidance and the 2024 MetALD Expert Position Statement. He serves as Vice-Chair of the AASLD Alcohol-Associated Liver Disease Special Interest Group and is a member of the editorial board of Liver Transplantation. Dr. Im is the founder of ALD-ALLY, an annual conference dedicated to improving care and fostering research for patients with alcohol use disorder and ALD. His research focuses on early liver transplantation for alcohol-associated hepatitis, metabolic liver disease, and strategies to improve outcomes in patients with advanced liver disease. Through his leadership, scholarship, and mentorship, Dr. Im continues to shape the evolving field of hepatology and liver transplantation.
About This Conference
Alcohol-associated liver disease (ALD) remains one of the leading causes of advanced liver disease and liver transplantation worldwide. Despite significant advances in understanding its pathogenesis and management, several aspects of ALD continue to generate debate among clinicians and researchers. This presentation will explore current controversies in ALD, including screening and diagnosis of alcohol use disorder, the role of biomarkers, management of alcohol-associated hepatitis, selection criteria for early liver transplantation, relapse prevention strategies, and emerging pharmacologic therapies. The session will also address evolving concepts such as MetALD, disparities in access to care, and the integration of multidisciplinary approaches to improve patient outcomes. Attendees will gain practical insights into navigating these challenging clinical scenarios while reviewing the latest evidence and guideline recommendations.